Taysha Gene Therapies (TSHA) EBITDA (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of EBITDA data on file, last reported at -$43.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 103.01% year-over-year to -$43.5 million; the trailing twelve-month figure through Mar 2026 stood at -$132.6 million (down 49.7% YoY), and the FY2025 full-year result was -$110.5 million, down 20.82% from the prior year.
• EBITDA slipped to -$43.5 million in Q1 2026, from -$28.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$16.2 million in Q4 2023 to a low of -$54.0 million in Q4 2022.
• A 5-year average of -$28.3 million and a median of -$25.5 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 69.9% in 2023 and sank 103.01% in 2026, its largest moves.
• Tracing TSHA's EBITDA over 5 years: stood at -$54.0 million in 2022, then surged by 69.9% to -$16.2 million in 2023, then decreased by 22.69% to -$19.9 million in 2024, then plunged by 41.98% to -$28.3 million in 2025, then tumbled by 53.66% to -$43.5 million in 2026.
• Business Quant data shows TSHA's EBITDA at -$43.5 million in Q1 2026, -$28.3 million in Q4 2025, and -$34.0 million in Q3 2025.